Endothelin plays a critical role in the pathogenesis of cardiovascular diseases, and endothelin-targeting therapies have been employed to treat these conditions with varying degrees of success.
Endothelin was first discovered more than 30 years ago as a potent vasoconstrictor. In subsequent years, three isoforms, two canonical receptors, and two converting enzymes were identified, and their basic functions were elucidated by numerous preclinical and clinical studies. Over the years, the endothelin system has been found to be critical in the pathogenesis of several cardiovascular diseases, including hypertension, pulmonary arterial hypertension, heart failure, and coronary artery disease. In this review, we summarize the current knowledge on endothelin and its role in cardiovascular diseases. Furthermore, we discuss how endothelin-targeting therapies, such as endothelin receptor antagonists, have been employed to treat cardiovascular diseases with varying degrees of success. Lastly, we provide a glimpse of what could be in store for endothelin-targeting treatment options for cardiovascular diseases in the future.
Haryono et al. (Mon,) conducted a review in Cardiovascular diseases. Endothelin-targeting therapies was evaluated. Endothelin plays a critical role in the pathogenesis of cardiovascular diseases, and endothelin-targeting therapies have been employed to treat these conditions with varying degrees of success.